Competitive intelligence and portfolio strategy
Active programs by phase, discontinued programs, regulatory dates and the sponsors behind a disease or target, with each drug counted once under all its names.
Individual plan, $249/seat/mo. Card required.
A landscape slide starts as a registry export and days of deduplication. A compound filed under a code name, a generic name and a brand name shows up as three competitors, and a discontinued program drops out of view. White space that looks real can be an artifact of naming.
Pages marked free open without an account. The rest open in the product, starting with a 14-day trial.
A condition page lists the lead sponsors and the drugs trialled in a disease beside its trial counts by phase and by start year, so the field in an indication can be read from one page. Diabetes Mellitus is a worked example. 22,120 registered trials study Diabetes Mellitus or one of its sub-conditions.
Free to read Conditions Open the Diabetes Mellitus page
A biomarker page separates FDA companion diagnostic assertions, curated cancer actionability, trial mentions and target-disease associations, so the biomarker rationale behind a program can be graded before it goes on a landscape. BRAF is a worked example of one gene's evidence split by type. The BRAF page lists 19 FDA companion diagnostic assertions today.
Free to read Biomarkers Open the BRAF page
A target page counts the programs aimed at it and charts them by phase, so the split between early and late work is visible, and it lists the companies developing against the target and the programs that were discontinued. The page labels its crowding counts as a floor on the field and not the whole of it.
In the product: Targets
The Program explorer lists development programs as drug and indication pairs, with a minimum-phase filter from any phase to Phase 4. Target pages also keep a Discontinued programs list, so dropped work stays in view.
In the product: Programs
A drug page folds one molecule's brands, trial variants and development programs into a single record, so a code name, a generic name and a brand name are counted once. That keeps the number of competitors on a landscape slide honest.
In the product: Chemical Entities
The Calendar shows when a competitor's FDA decision is due, with the drug and sponsor attached where the match holds up. The public lane is built from SEC 8-K and 6-K filings, and the Individual plan adds the licensed Benzinga catalyst calendar, shown with its attribution.
In the product: Calendar
Programs are built from public registries and filings. A program a company has never disclosed publicly will not appear, and crowding counts on a target page are a floor on the field.
Every answer above marked "In the product" opens with the Individual plan.
Individual plan, $249/seat/mo, card required.
